Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$85.79M$85.79Mderived+20.1% vs Q4 2022 Net Income-$18.75M-$18.75MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$15,288,000N/M Operating Cash Flowderived-$3,893,000N/M Free Cash Flowderived-$4,754,000N/M Margins · derivedOperating margin-17.8%+17.3 pt vs Q4 2022
Net margin-21.9%−6.5 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 28, 2024 · 88 d after period end